Scarica l'app Stockscreener
50.80
5.33%
2.57
Dopo l'orario di chiusura:
50.90
0.10
+0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$48.23
Aprire:
$49.02
Volume 24 ore:
8.15M
Relative Volume:
0.76
Capitalizzazione di mercato:
$20.15B
Reddito:
$1.94B
Utile/perdita netta:
$-2.82B
Rapporto P/E:
-6.9956
EPS:
-7.2617
Flusso di cassa netto:
$-2.08B
1 W Prestazione:
-1.05%
1M Prestazione:
-5.17%
6M Prestazione:
+96.67%
1 anno Prestazione:
+79.19%
Intervallo 1D:
$47.96
$51.62
Intervallo di 1 settimana:
$47.14
$54.68
Portata 52W:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
50.80 | 19.13B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
446.54 | 112.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
772.64 | 79.21B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
730.25 | 43.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.87 | 41.92B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.52 | 33.05B | 606.42M | -1.28B | -997.58M | -6.403 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna (MRNA) Experiences Bearish Sentiment Among Option Traders - GuruFocus
Oil Tumbles, Nasdaq 100 Jumps 3% As Iran Says It's Ready To Halt Hostilities: 10 Stocks Moving - Benzinga
Moderna, Pfizer Press to Toss Bayer’s Covid-Shot Patent Suits - Bloomberg Law News
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability - FinancialContent
3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next - 24/7 Wall St.
Moderna, Inc. Trade Ideas — BSESOF:0QF - TradingView
Moderna's Spikevax Vaccine: Current Market Position, Strategic Developments and Investor Relevance i - AD HOC NEWS
EMA panel recommendation for mCOMBRIAX approval sees Moderna stock fall 7.49% - Traders Union
MRNA Stock Quote Price and Forecast - CNN
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Moderna shares slide as investors weigh recent legal-cost clarity against fresh regulatory uncertainty - Quiver Quantitative
Stock Traders Purchase Large Volume of Moderna Call Options (NASDAQ:MRNA) - MarketBeat
How (MRNA) Movements Inform Risk Allocation Models - Stock Traders Daily
ETFs Investing in Moderna, Inc. Stocks - TradingView
Azenta, 10x Genomics, PacBio, Oscar Health, and Moderna Shares Plummet, What You Need To Know - finance.yahoo.com
What is behind Moderna stock's recent drop in value today - Traders Union
Vanguard realignment: Vanguard reports 0 MRNA shares (MRNA) - Stock Titan
ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential? - finance.yahoo.com
Moderna Inc. stock: mRNA pioneer's strategic pivot amid biotech sector challenges and vaccine market - ad-hoc-news.de
Moderna Stock is Soaring. Is It Too Late to Buy? - The Globe and Mail
Metagenomi Can’t Ax IPO Investor Suit Over Moderna Partnership - Bloomberg Law News
What is behind Moderna stock's recent gain in value today - tradersunion.com
Moderna stands as the best performing large-cap healthcare stock YTD (XLV:NYSEARCA) - Seeking Alpha
Moderna, Heidrick & Struggles Execs Talk AI Execution - WSJ
Moderna Inc. stock faces analyst pressure amid patent settlement with Arbutus Biopharma - ad-hoc-news.de
Moderna's Spikevax Vaccine: Current Status and Future Prospects in mRNA Technology Evolution - AD HOC NEWS
Lobbying Update: $100,000 of MODERNA INC. lobbying was just disclosed - Quiver Quantitative
Roivant Sciences, Genevant, Arbutus, and Moderna Settle International Patent Litigation – Key Terms and Confidentiality Details - Minichart
Moderna's Spikevax Vaccine: Latest Developments and Future Prospects as of March 2026 - AD HOC NEWS
ABUS: $2.25B Moderna settlement and improved net loss highlight strong 2025 performance - TradingView
ABUS: Secured $950M settlement with Moderna, reduced net loss, and streamlined operations in 2025 - TradingView
Arbutus Biopharma (Nasdaq: ABUS) trims 2025 loss after $2.25B Moderna settlement - Stock Titan
Moderna settlement reshapes Arbutus Biopharma (ABUS) with $950M payout - Stock Titan
Hudson Bay Capital Management Reduces Moderna Stake - National Today
Hudson Bay Capital Management LP Lowers Stake in Moderna, Inc. $MRNA - MarketBeat
VIX Spike: Is Moderna Inc a momentum stock2026 Volume & AI Driven Stock Price Forecasts - baoquankhu1.vn
MODERNA, INC. (MRNA) - MSN
Rate Hike: Should you avoid Moderna Inc stock right nowAnalyst Upgrade & Safe Entry Trade Reports - baoquankhu1.vn
Trade Recap: Is now the right time to enter Moderna Inc2026 Dividend Review & Daily Stock Momentum Reports - baoquankhu1.vn
Moderna Inc. stock faces headwinds amid pipeline delays and FDA vaccine policy shifts - AD HOC NEWS
Aug Macro: Can Moderna Inc continue delivering strong returnsWeekly Stock Summary & Low Drawdown Investment Ideas - baoquankhu1.vn
Promising Biotech Stocks To Keep An Eye OnMarch 21st - MarketBeat
Moderna's Spikevax Vaccine Faces Renewed Scrutiny Amid Biotech Sector Momentum and Safety Data Revel - AD HOC NEWS
Moderna to pay about $1 billion to settle Arbutus litigation - MSN
COMMENTARY: An erratic FDA is a threat to innovation - Jefferson City News Tribune
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Therapeutics Sector Q4 Results: Revenue Beats Amid Market Stability - IndexBox
Therapeutics Stocks Q4 Teardown: Moderna (NASDAQ:MRNA) Vs The Rest - Yahoo Finance
What triggered Moderna shares' latest price pullback - Traders Union
Why Moderna (MRNA) Is Down 6.4% After Cancer Vaccine Data And Flu Shot’s Expedited FDA Review - Yahoo Finance UK
Pfizer vs Moderna 2026: Pipeline Prospects After Vaccine Sales DropNews and Statistics - IndexBox
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moderna Inc Azioni (MRNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Klinger Shannon Thyme | Chief Legal Officer |
Mar 02 '26 |
Sale |
52.29 |
13,885 |
726,047 |
59,689 |
4.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):